According to the previous publications, gp96 serves as an oncogene to facilitate BC progression (10, 11) and enhance paclitaxel-resistance in ovarian cancer (12), which are supported by our results that gp96 was upregulated in the paclitaxel-resistant BC (PR-BC) tissues and cells, in contrast with their paclitaxel-sensitive BC (PS-BC) counterparts. The gene discussed is HSP90B1; the disease is ovarian cancer.